Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-25

Study Completion Date

2024-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts. Combined with hepatic arterial infusion chemotherapy (HAIC), this study is conducted to assess the efficacy and safety of this regimen in patients with unresectable colorectal cancer liver metastases as the third-line therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

NCT05435313

Colorectal Cancer

ACTIVE_NOT_RECRUITING PHASE2

A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy

NCT05511051

Colorectal Cancer

UNKNOWN PHASE2

Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer

NCT06423937

Colorectal Cancer

NOT_YET_RECRUITING PHASE2

Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer

NCT05928312

Advanced Colorectal Cancer

NOT_YET_RECRUITING NA

Study of Fruquintinib in Patients With Metastatic Colorectal Cancer

NCT02196688

Colorectal Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be a single-arm, open-label, phase II study. This study will be divided into 2 stages: dose exploration and dose expansion. In the dose exploration stage, "3+3 dose escalation" design will be applied to determined the maximum tolerated dose (MTD) of fruquintinib for next stage:

Cohort A: HAIC + fruquintinib 3mg QD, 3 weeks on/1 week off (3w/1w). Cohort B: HAIC + fruquintinib 4mg QD, 3w/1w. Cohort C: HAIC + fruquintinib 5mg QD, 3w/1w.

All subjects of this study will be permitted to continue therapy with only safety monitoring and assessments for progression, if the product is well tolerated and the subject has stable disease or better.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Colorectal Carcinoma Liver Metastasis Colon Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HAIC combined with Fruquintinib

HAIC with fruquintinib until progression. Fruquintinib should be administrated within 1 week after HAIC.

Group Type EXPERIMENTAL

Fruquintinib

Intervention Type DRUG

Fruquintinib is a capsule in the form of 1mg and 5mg, once a day, 3 week on/1 week off.

Hepatic Arterial Infusion Chemotherapy

Intervention Type PROCEDURE

HAIC is a locoregional therapy for colorectal cancer liver metastasis. Oxaliplatin 85 mg/m\*2 + 5-FU 2000 mg/m\*2, Q4W

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fruquintinib

Fruquintinib is a capsule in the form of 1mg and 5mg, once a day, 3 week on/1 week off.

Intervention Type DRUG

Hepatic Arterial Infusion Chemotherapy

HAIC is a locoregional therapy for colorectal cancer liver metastasis. Oxaliplatin 85 mg/m\*2 + 5-FU 2000 mg/m\*2, Q4W

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HMPL-013 HAIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female, age ≥ 18 years and ≤75, at the time of study entry.
2. Histologically or cytologically documented advanced colorectal carcinoma with unresectable liver metastasis (existence of extrahepatic metastasis is acceptable).
3. Previously received 2 lines of standard chemotherapy, including 5-FU, oxaliplatin, and irinotecan.
4. Subjects must have at least one measurable lesion per RECIST v1.1.
5. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
6. Estimated life expectancy of ≥12 weeks.
7. Adequate organ functions verified by laboratory tests within 7 days before the first intervention, including bone marrow, liver and kidney function, and coagulation function
8. Female subjects of childbearing potential who are sexually active with a nonsterilized male partner must use an acceptable method of contraception from screening, and must agree to continue using such precautions for 90 days after the final dose of investigational product.
9. Written and signed informed consent.

Exclusion Criteria

1. ANC\<1.5×10\*9/L, PLT\<80×10\*9/L, or Hb\<9g/dL; no blood infusion within 2 weeks.
2. TBil\>2.5 × ULN.
3. AST or ALT\>5 × ULN.
4. Serum Cr\>1.5 × ULN, or CrCl\<50 ml/min (calculated by Cockcroft-Gault equation)
5. APTT or PT\> 1.5 × ULN.
6. Clinically significant electrolyte abnormalities determined by investigators.
7. Proteinuria ≥ 2+ (1.0g/24hr).
8. Hypertension that cannot be controlled by drugs, which is specified as: systolic blood pressure ≥ 140 mmHg and / or diastolic blood pressure ≥ 90 mmHg
9. Active gastrointestinal ulceration, ulcerative colitis, or gastrointestinal bleeding; potential gastrointestinal bleeding or perforation determined by investigators.
10. History of arterial thrombosis or deep venous thrombosis within 6 months before enrollment; evidence of hemorrhagic tendency or receiving anticoagulant therapy within 2 months before enrollment.
11. Stroke or transient cerebral ischemia occurred within 12 months before enrollment.
12. History of cardiovascular disease within 6 months before enrollment, including congestive heart failure (NYHA grade\>2), acute myocardial ischemia, severe/unstable angina or CABG; or LVEF\<50%.
13. Uncontrollable malignant ascites, pleural effusion, or pericardial effusion (determined by investigators).
14. Previous treated with VEGFR inhibitors.
15. Other malignant tumors in the past 5 years, except skin basal cell or squamous cell carcinoma after radical surgery, or cervical carcinoma in situ.
16. Evidence of CNS metastasis.
17. Active infection, such as acute pneumonia, active stage of HBV/HCV.
18. Pregnant or lactating women.
19. By judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the patient or affect the completion of the study.
20. Severe mental illness.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No